




AKADÉMIAI KIADÓ

# Resistome analysis of *Escherichia coli* isolates from layers in Hungary

ÁDÁM KEREK<sup>1,2\*</sup> , ÁBEL SZABÓ<sup>1</sup>, KRISZTIÁN BÁNYAI<sup>1,2,4</sup>,  
ESZTER KASZAB<sup>2,3,7</sup>, KRISZTINA BALI<sup>2,7</sup>, MÁRTON PAPP<sup>2,5</sup>,  
LÁSZLÓ KOVÁCS<sup>6</sup> and ÁKOS JERZSELE<sup>1,2</sup>

Acta Veterinaria  
Hungarica

72 (2024) 1, 1-10

DOI:

[10.1556/004.2024.00988](https://doi.org/10.1556/004.2024.00988)

© 2024 The Author(s)

<sup>1</sup> Department of Pharmacology and Toxicology, University of Veterinary Medicine, István street 2, H-1078 Budapest, Hungary

<sup>2</sup> National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine Budapest, Hungary

<sup>3</sup> One Health Institute, University of Debrecen, Nagyerdei krt. 98., Debrecen, H-4032, Hungary

<sup>4</sup> Veterinary Medical Research Institute, Hungária krt. 21, H-1143, Budapest, Hungary

<sup>5</sup> Centre for Bioinformatics, University of Veterinary Medicine, István street 2, H-1078 Budapest, Hungary

<sup>6</sup> Department of Animal Hygiene, Herd Health and Mobile Clinic, University of Veterinary Medicine, István street 2, H-1078 Budapest, Hungary

<sup>7</sup> Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, István u 2., Budapest, H-1078, Hungary

## RESEARCH ARTICLE



Received: 27 August 2023 • Accepted: 28 February 2024

Published online: 5 April 2024

### ABSTRACT

The authors aimed to investigate eight strains of *Escherichia coli* (*E. coli*) strains from Hungarian layer flocks for antimicrobial resistance genes (ARG), using metagenomic methods. The strains were isolated from cloacal swabs of healthy adult layers. This study employed shotgun sequencing-based genetic and bioinformatic analysis along with determining phenotypic minimum inhibitory concentrations. A total of 59 ARGs were identified in the eight *E. coli* isolates, carrying ARGs against 15 groups of antibiotics. Among these, 28 ARGs were identified as transferable. Specifically, four ARGs were plasmid-derived, 18 ARGs were phage-derived and an additional six ARGs were predicted to be mobile, contributing to their mobility and potential spread between bacteria.

### KEYWORDS

resistome, antibiotic resistance genes, ARGs, antibiotics, *Escherichia coli*

## INTRODUCTION

The discovery of antibiotics made it possible to treat bacterial infectious diseases, but over time, resistance has become widespread (Micoli et al., 2021), and is now one of the most significant global public health issues (von Wintersdorff et al., 2016). Even the most conservative estimates suggest that without any significant intervention, by 2050 nearly 10 million people will die from antimicrobial resistance (AMR) each year (O'Neill, 2014). The resistance mechanisms and genes can be so abundant, that in a single *Escherichia coli* (*E. coli*) strain, almost all known resistance mechanisms can be found, with 68 different resistance genes, making it resistant against 16 widely used antibiotics (Zhang et al., 2019). To reduce the possibilities of resistance development, a number of antibiotic alternatives have emerged, including the use of vaccines as a preventive measure (Micoli et al., 2021), which can prevent bacteria from multiplying to the point where resistance mutations are developed

\*Corresponding author.

E-mail: [kerek.adam@univet.hu](mailto:kerek.adam@univet.hu)



(Rappuoli et al., 2017). It should also be mentioned that the use of antibiotic resistance genes as marker genes in live bacterial vaccines is strongly discouraged, as these genes can be transferred to humans (El-Attar et al., 2012).

It is also important to note that correlations have been found between several resistance genes and virulence genes, which may lead to the selection of bacteria with different virulence genes (Boerlin et al., 2005). However, in case of some intestinal pathogenic *E. coli* strains it has been observed that the more resistance genes a bacterium has, the less virulence genes it carries (Nagy et al., 2015).

Second-generation sequencing (NGS, next generation sequencing) is a fast parallel sequencing technique, also known as deep or shallow sequencing (Marguerat et al., 2008). New algorithms are continuously being developed to align huge amounts of data, in the form of short reads, identify operons and recombinant variants and build phylogenetic trees based on single nucleotide polymorphisms (SNP), among others (Chan, 2009). At first, sequencing was used for the comprehensive detection of ARGs of *E. coli* by several authors (Veenemans et al., 2014; Hernández-Fillor et al., 2021; Alvarez Narvaez et al., 2022). More recently, the possibility of genome sequencing has also enabled the development of safe vaccines (Prachi et al., 2013) to test strains for efficacy, primarily for virulence factors (Bidmos et al., 2018), but without putting an emphasis on transferable antimicrobial resistance. We aimed to investigate the resistome (complete ARG carriage) of different *E. coli* strains isolated from cloacal swabs of healthy adult poultry using NGS technique and to explore the risks of transmissible antimicrobial resistances for human and for animal health, including the theoretical possibility of using such bacteria for the development of live vaccine candidates.

## MATERIALS AND METHODS

### Strains

Eight commensal *E. coli* isolates were used in this study, isolated from cloacal swab samples from healthy layer hens in 2020, using Coliform Selective Agar (Biolab Zrt., Budapest, Hungary). These samples were collected from different large laying flocks in different geographical regions of Hungary. They were chosen from among strains collected from flocks based on preliminary phenotypic susceptibility

testing. The selection focused on strains demonstrating the highest resistance to antibiotic agents commonly used in poultry.

### Sequencing

DNA from bacterial suspension was isolated using the QIAmp DNA kit (Qiagen, Germany), following the manufacturer's protocol. DNA extraction was performed in a Qiagen Tissue Lyzer LT at 50 Hz for 10 min, with each sample eluting at 50 µg mL<sup>-1</sup>. Finally, fluorometric quantification was performed using Qubit<sup>®</sup> dsDNA BR Assay kit (Thermo Fisher SSC, Budapest, Hungary).

DNA libraries were prepared using Illumina<sup>®</sup> Nextera XT DNA Library Preparation Kit (Illumina, San Diego, USA). Indexes were used to label DNA fragments using the Nextera XT Index Kit v2 Set C (Illumina, San Diego, USA). The resulting indexed DNA library was purified using Gel/PCR DNA Fragments Extraction Kit (Geneaid Biotech, Xinpei, Taiwan), following the column purification protocol; and then Qubit<sup>®</sup> dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, USA) was used for fluorometric quantification for quality control. Paired-end reads generated from the DNA were determined using the Illumina NextSeq 500 sequencer (Sahin-Tóth et al., 2021).

### Bioinformatics data processing

Initial quality control of the raw sequences was conducted using FastQC v0.11.9 software (Andrews, 2012), followed by the elimination of sequences with subpar quality using TrimGalore v0.6.7 (Krueger et al., 2021). The read sequences were assembled into longer contigs using MEGAHIT v1.2.9 (Li et al., 2015). For contig quality assessment (Table 1), the QUAST software was employed (Gurevich et al., 2013). All conceivable Open Reading Frames (ORFs) were subsequently identified from the resulting contigs utilizing Prodigal v2.6.3 (Hyatt et al., 2010) and deposited (1028257 BioProject ID).

Identification of ARGs within the ORFs was performed using Resistance Gene Identifier (RGI) v5.1.0 against the CARD database (downloaded on 23/04/2021) (Alcock et al., 2020). Only genes meeting the STRICT threshold criteria established by the CARD database were considered. Furthermore, these genes were only taken into account if they exhibited sequence identity and coverage of at least 95%.

To assess the potential mobility of identified resistance genes, MobileElementFinder (v1.0.3) (Johansson et al., 2021)

Table 1. Quality characteristics of contigs

Strain	No of trimmed reads	No of contigs	Coverage	NG <sub>50</sub>	NG <sub>75</sub>	LG <sub>50</sub>	LG <sub>75</sub>
1	7,783,363	306	91.973	41,186	22,355	37	75
2	3,603,219	249	86.087	77,510	43,464	20	39
3	3,840,473	239	85.88	98,058	52,321	19	34
4	3,412,510	221	85.25	85,768	52,888	16	33
5	3,632,208	215	83.254	100,786	52,218	13	29
6	3,406,337	203	88.6	83,902	55,553	17	34
7	3,440,737	138	82.821	100,453	62,485	14	28
8	3,815,334	312	83.328	88,200	44,242	19	37



was employed, predicting Mobile Genetic Elements (MGEs) on the contigs. For evaluating mobility, only ARGs within the range of the longest composite transposon (Tn1681, 24,488 nucleotides in length), typical for *E. coli* in the database, were considered potentially mobile. Additionally, contigs' plasmid origin was investigated using PlasFlow v1.1 software (Krawczyk et al., 2018), while the presence of phage genomes on the contigs was determined using VirSorter v2.2.2 (Roux et al., 2015) software.

As a quality control, we looked at the assembly size (i.e. how many nucleotides there are in the assembly).  $LG_{50}$  (length genome metrics) is the least number of contigs that are 50% of the genome length, if we sort the contigs by size.  $NG_{50}$  (number genome metrics) is the length of the shortest of these contigs (i.e. those that reach 50% of the genome length). The  $NG_{75}$  and  $LG_{75}$  values are relative to 75% of the genome. The abbreviations  $LG_{50}$  and  $LG_{75}$  signify that the shortest contigs reaching 50% and 75% of the genome length are determined when contigs are sorted by size.  $NG_{50}$  is always greater than or equal to  $NG_{75}$  and  $LG_{50}$  is always less than or equal to  $LG_{75}$ .

### Minimum inhibitory concentration determination

The phenotypic manifestation of AMR was evaluated by determining the minimum inhibitory concentration (MIC) value of each bacterial strain against specific antibiotics. The testing protocol adhered to the methodology outlined by the CLSI (Clinical and Laboratory Standards Institute, 2018).

Breakpoints for interpretation were established using criteria from both the CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2015) (Table 4).

The active substances used for testing (Merck KGaA, Darmstadt, Germany) included amoxicillin and amoxicillin-clavulanic acid (in a 2:1 ratio) in phosphate buffer solution at pH 6 ( $0.1 \text{ mol L}^{-1}$ ); cefquinome, cefotaxime, oxytetracycline, doxycycline, gentamicin, and colistin dissolved in distilled water; imipenem in phosphate buffer solution at pH 7.2 ( $0.01 \text{ mol L}^{-1}$ ); sulfamethoxazole dissolved in hot water with a few drops of  $2.5 \text{ mol L}^{-1}$  NaOH; trimethoprim dissolved with  $0.05 \text{ mol L}^{-1}$  HCl; and a potent sulphonamide (sulfamethoxazole and trimethoprim in a 20:1 ratio) dissolved as previously described. Enrofloxacin dissolution was prepared with a few drops of  $1 \text{ mol L}^{-1}$  NaOH solution in distilled water.

The MIC determination range was as follows:  $32\text{-}0.06 \mu\text{g mL}^{-1}$  for amoxicillin, amoxicillin-clavulanic acid, gentamicin, oxytetracycline and doxycycline;  $16\text{-}0.03 \mu\text{g mL}^{-1}$  for cefquinome, colistin, cefotaxime, imipenem and enrofloxacin;  $128\text{-}0.25 \mu\text{g mL}^{-1}$  for sulfamethoxazole, trimethoprim and the potent sulphonamide.

## RESULTS

The frequency of each resistance mechanism within each antibiotic group is presented in Fig. 1, while the identified ARGs are comprehensively listed in Table 2. In this analysis,




Fig. 1. Frequency of genes encoding major antimicrobial resistance mechanisms by antibiotic group



Table 2. List of antimicrobial resistance genes and gene products identified in the eight *E. coli* isolates investigated. (The number of isolates with the respective genes identified are in parentheses)

Antimicrobial resistance genes and gene products	Coverage %	Sequence identity %	M <sup>1</sup>	Ph <sup>2</sup>	Pl <sup>3</sup>	Resistance class *	Antibiotic mechanism *
<i>acrB</i> (8)	100	100				fluoroquinolone, cephalosporin, glycylicycline, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic efflux
<i>acrD</i> (8)	100	99.81		+		aminoglycoside	antibiotic efflux
<i>acrE</i> (8)	100	100		+		fluoroquinolone, cephalosporin, cephamycin, penam	antibiotic efflux
<i>acrF</i> (8)	100	99.61		+		fluoroquinolone, cephalosporin, cephamycin, penam	antibiotic efflux
<i>acrS</i> (7)	100	100				fluoroquinolone, cephalosporin, glycylicycline, cephamycin, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic efflux
<i>bacA</i> (8)	100	100				peptide antibiotic	antibiotic target alteration
<i>baeR</i> (8)	100	99.58		+		aminoglycoside, aminocoumarin	antibiotic efflux
<i>baeS</i> (8)	100	99.14		+		aminoglycoside, aminocoumarin	antibiotic efflux
<i>cpxA</i> (8)	100	100		+		aminoglycoside, aminocoumarin	antibiotic efflux
<i>CRP</i> (7)	100	99.52				macrolide, fluoroquinolone, penam	antibiotic efflux
<i>emrA</i> (8)	100	99.74				fluoroquinolone	antibiotic efflux
<i>emrB</i> (8)	100	100				fluoroquinolone	antibiotic efflux
<i>emrK</i> (8)	100	99.72		+		tetracycline	antibiotic efflux
<i>emrR</i> (7)	100	100				fluoroquinolone	antibiotic efflux
<i>emrY</i> (8)	100	99.8		+		tetracycline	antibiotic efflux
<i>eptA</i> (8)	100	99.63				peptide antibiotic	antibiotic target alteration
<i>acrA</i> (8)	100	100				fluoroquinolone, cephalosporin, glycylicycline, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic target alteration, antibiotic efflux
<i>acrR</i> (8)	100	100				fluoroquinolone, cephalosporin, glycylicycline, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic target alteration, antibiotic efflux
<i>ampC</i> (5)	100	97.35	+			cephalosporin, penam	antibiotic inactivation
<i>ampC1</i> (3)	99.77	99.08		+		cephalosporin, penam	antibiotic inactivation
<i>ampH</i> (7)	100	99.74				cephalosporin, penam	antibiotic inactivation
<i>cyaA</i> (3)	100	99.29				fosfomycin	antibiotic target alteration
EF-Tu (5)	96.33	99.75				elfamycin	antibiotic target alteration
<i>emrE</i> (8)	100	98.18		+		macrolide	antibiotic efflux
<i>glpT</i> (8)	100	99.78				fosfomycin	antibiotic target alteration
<i>gyrA</i> (3)	100	99.77				fluoroquinolone	antibiotic target alteration
<i>marR</i> (8)	100	98.61				fluoroquinolone, cephalosporin, glycylicycline, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic target alteration, antibiotic efflux
<i>mdfA</i> (8)	100	96.59				tetracycline, benzalkonium chloride, rhodamine	antibiotic efflux
<i>soxR</i> (8)	100	100		+		fluoroquinolone, cephalosporin,	antibiotic target alteration,
<i>soxS</i> (8)	100	100		+		glycylicycline, penam, tetracycline, rifamycin, phenicol, triclosan	antibiotic efflux

<sup>1</sup>M: Mobile genetic elements; <sup>2</sup>Ph: located on Phage; <sup>3</sup>Pl: located on Plasmid.

\* The Comprehensive Antibiotic Resistance Database (Alcock et al., 2023).

Antibiotic resistance genes (ARG) and gene products	Coverage %	Sequence identity %	M <sup>1</sup>	Ph <sup>2</sup>	Pl <sup>3</sup>	Resistance class*	Antibiotic mechanism*
<i>uhpT</i> (1)	100	99.57	+			fosfomycin	antibiotic target alteration
<i>evgA</i> (8)	100	100				macrolide, fluoroquinolone,	antibiotic efflux
<i>evgS</i> (8)	100	99.42				penam, tetracycline	
<i>gadW</i> (7)	100	96.28					
<i>gadX</i> (1)	100	98.54					

(continued)



Table 2. Continued

Antibiotic resistance genes (ARG) and gene products	Coverage %	Sequence identity %	M <sup>1</sup>	Ph <sup>2</sup>	Pl <sup>3</sup>	Resistance class*	Antibiotic mechanism*
H-NS (8)	100	100				macrolide, fluoroquinolone, cephalosporin, cephamycin, penam, tetracycline	antibiotic efflux
<i>kdpE</i> (7)	100	99.11	+			aminoglycoside	antibiotic efflux
<i>marA</i> (8)	100	100				fluoroquinolone, monobactam, carbapenem, cephalosporin, glycylicline, cephamycin, penam, tetracycline, rifamycin, phenicol, triclosan, penem	antibiotic efflux, reduced permeability to antibiotic
<i>mdtA</i> (6)	100	99.28		+		aminocoumarin	antibiotic efflux
<i>mdtB</i> (8)	100	100		+		aminocoumarin	antibiotic efflux
<i>mdtC</i> (8)	100	99.41		+		aminocoumarin	antibiotic efflux
<i>mdtE</i> (8)	100	100				macrolide, fluoroquinolone, penam	antibiotic efflux
<i>mdtF</i> (7)	100	99.81				macrolide antibiotic; fluoroquinolone antibiotic; penam	antibiotic efflux
<i>mdtG</i> (8)	100	100	+	+		fosfomycin	antibiotic efflux
<i>mdtH</i> (8)	100	100		+		fluoroquinolone	antibiotic efflux
<i>mdtM</i> (6)	100	97.8		+		fluoroquinolone, lincosamide antibiotic, nucleoside antibiotic, acridine dye, phenicol, disinfecting agents and intercalating dyes	antibiotic efflux
<i>mdtN</i> (8)	100	99.42		+		nucleoside antibiotic,	antibiotic efflux
<i>mdtO</i> (7)	95.75	98.62		+		acridine dye, disinfecting agents and intercalating dyes	
<i>mdtP</i> (8)	100	98.16		+			
<i>msbA</i> (8)	100	100	+	+		nitroimidazole antibiotic	antibiotic efflux
<i>pmrF</i> (8)	100	100				peptide antibiotic	antibiotic target alteration
<i>qnrS1</i> (1)	100	100	+		+	fluoroquinolone	antibiotic target protection
<i>sul2</i> (2)	100	100	+		+	sulfonamide antibiotic	antibiotic target replacement
<i>bla<sub>TEM-1</sub></i> (1)	100	100	+		+	monobactam, cephalosporin, penam, penem	antibiotic inactivation
<i>tetB</i> (2)	100	99.25				tetracycline	antibiotic efflux
<i>tetR</i> (1)	99.52	100				tetracycline	antibiotic target alteration, antibiotic efflux
<i>tolC</i> (8)	99.6	100	+			macrolide, fluoroquinolone, aminoglycoside, carbapenem, cephalosporin, glycylicline, cephamycin, penam, tetracycline, peptide antibiotic, aminocoumarin, rifamycin, phenicol, triclosan, penem	antibiotic efflux
<i>ugd</i> (7)	100	99.23	+	+		peptide antibiotic	antibiotic target alteration
<i>yojI</i> (8)	100	99.82				peptide antibiotic	antibiotic efflux

<sup>1</sup>M: Mobile genetic elements; <sup>2</sup>Ph: located on Phage; <sup>3</sup>Pl: located on Plasmid.

\* The Comprehensive Antibiotic Resistance Database (Alcock et al., 2023).



a total of eight distinct *E. coli* strains were subjected to examination, with the majority of the resistance genes listed in the table being detected across all strains.

The majority of ARGs were associated with the fluoroquinolone group within The Antimicrobial Advice Ad Hoc Expert Group (AMEG) class B, holding significant implications for both human and animal health. Notably, 73% of these ARGs were attributed to efflux pumps, a critical component of resistance mechanisms. Furthermore, within this group, which encompasses generation 3–4 cephalosporins, 57.8% of  $\beta$ -lactam ARGs were identified as encoding cephalosporin resistance. Within the same category, the occurrence of genes encoding resistance to polymyxins (colistin) reached six, constituting 3.7% of the total genes detected. Collectively, the total count of ARGs targeting drug groups categorized in the AMEG class B amounted to 50, representing 30.9% of all identified genes.

In total, we detected a diverse spectrum of 59 unique ARGs across the eight sequenced bacterial strains. These 59 genes collectively comprised the entirety of the distinct ARGs identified. Notably, some genes were found to be present in multiple strains, contributing to the total count of 162 ARGs detected within the dataset encompassing all eight strains. The predominant resistance mechanism was efflux pumps, accounting for 110 of the identified genes (67.9%). Among these, 22 genes were associated with fluoroquinolones (13.6%), 17 with  $\beta$ -lactams (10.5%) and the third most frequent occurrence was observed for tetracyclines (16, 9.9%). The prevalence of mutation or enzymatic target alteration type resistance mechanisms was also most notable among the aforementioned drug groups. The differences between the individual gene pool of each strain, compared to the total of 59 resistance genes identified are summarised in Table 3.

Table 3. Antimicrobial resistance genes not detected in the individual eight *E. coli* strains studied relative to their total number of AMR genes

Differences for all 59 genes identified	
Strains	Missing genes
1. Total genes: 49	<i>ampC1, ampH, cyaA, EF-Tu, gyrA, uhpT, gadW, mdtF, qnrS1, bla<sub>TEM-1</sub></i>
2. Total genes: 48	<i>CRP, ampC, gyrA, uhpT, gadX, kdpE, qnrS1, bla<sub>TEM-1</sub>, sul2, tetB, tetR</i>
3. Total genes: 51	<i>gyrA, uhpT, gadX, qnrS1, bla<sub>TEM-1</sub>, sul2, tetB, tetR</i>
4. Total genes: 50	<i>acrS, ampC, uhpT, gadX, qnrS1, bla<sub>TEM-1</sub>, sul2, tetB, tetR</i>
5. Total genes: 48	<i>ampC1, cyaA, EF-Tu, uhpT, gadX, mdtO, qnrS1, bla<sub>TEM-1</sub>, sul2, tetB, tetR</i>
6. Total genes: 49	<i>ampC, ampC1, cyaA, gyrA, uhpT, gadX, qnrS1, bla<sub>TEM-1</sub>, tetB, tetR</i>
7. Total genes: 46	<i>emrR, ampC1, cyaA, EF-Tu, uhpT, gyrA, gadX, qnrS1, bla<sub>TEM-1</sub>, mdtM, sul2, tetB, tetR</i>
8. Total genes: 50	<i>ampC1, cyaA, uhpT, gadX, mdtA, mdtM, sul2, tetR, ugd</i>

Moreover, we identified ARGs responsible for enzymatic inactivation against specific  $\beta$ -lactam antibiotics. Particularly significant were the two reduced permeability genes, *soxS* and *marA*, which exhibited their role in conferring resistance against fluoroquinolones,  $\beta$ -lactams, tetracyclines, aminoglycosides, phenicol and rifamycin. A single target replacement gene, *sul2*, was associated with sulphonamides. Additionally, a singular instance of target protection was found, specifically the *qnrS1* gene that contributed to fluoroquinolone resistance. Regarding their origin, 10 of the identified genes were associated with MGEs (6.2%), 23 were located on phage (14.2%) and 3 were located on plasmid (1.9%). Interestingly, three genes displayed both MGEs and were located on sequences of phage attributes (1.9%), while another three genes exhibited dual MGEs and were located on sequences of plasmid characteristics (1.9%). In our assessment, matches with a coverage above 98% and sequence identity above 98% were considered for analysis.

Upon comparing the phenotypic test results (Table 4) with the identified resistance genes, a clear alignment emerged between putative resistance genes and their corresponding high MIC values. This suggests that the genes potentially accountable for the observed resistance are closely matched with the individual elevated MIC levels.

For instance, in the case of amoxicillin and amoxicillin-clavulanic acid, the prominence of  $\beta$ -lactamase overproduction, particularly attributed to the *ampC* gene, is indicative of its responsibility. However, no discernible increase in MIC value was observed with cephalosporins. Fortunately, low MIC value was observed with colistin, too. Regarding imipenem resistance, the activation of efflux pumps (*soxS, marA, tolC*) could be suspected. A similar trend was inferred for resistance to aminoglycosides and tetracyclines, with the *acrD* and *kdpE* genes associated with the former and the *tetB, tetR* and *mdfA* genes associated with the latter. For fluoroquinolone resistance observed in a single strain, an efflux pump mechanism - involving the *acrA, acrB*, and *tolC* gene - could be presumed.

## DISCUSSION

Genes responsible for enzymatic inactivation were found only against  $\beta$ -lactams (*ampC, ampC1, ampH, bla<sub>TEM-1</sub>* genes). Genes responsible for permeability reduction were found for fluoroquinolones,  $\beta$ -lactams, tetracyclines, aminoglycosides, phenicols and rifamycin (*soxS, marA* genes). Target site modification occurred only against sulphonamides by the *sul2* gene that causes resistance of dihydropteroate synthase to sulphonamides and is usually on small plasmids (Sköld, 2001). The *qnrS1* gene is usually a fluoroquinolone resistance gene on a plasmid preventing the binding of the drug by protecting the target of antibiotic action (Hata et al., 2005).

MIC values determined in phenotypic testing reflect the expression of individual resistance genes. In the case of amoxicillin and amoxicillin-clavulanic acid, the observed resistance is due to the *ampC, ampH* and *bla<sub>TEM-1</sub>* genes, of



Table 4. Phenotypic analysis of strains and comparison of results with sequencing results. Data highlighted in red are considered resistant


Antibiotic	MIC value (µg/ml) per strain								Break-point µg/ml	Possible genetic background of phenotypic expression		
	1.	2.	3.	4.	5.	6.	7.	8.		Genes	Type of resistance	
1. amoxicillin	4	2	1	1	2	2	16	>32	≥8 <sup>4</sup>	<i>ampC</i> <sup>3</sup> <i>ampH</i> <sup>1</sup> <i>bla</i> <sub>TEM-1</sub> <sup>1,3</sup>	β-lactamase	
2. amoxicillin-clavulanic acid	8	4	4	4	4	4	8	>32	≥8 <sup>4</sup>			
3. cefquinom	<0.06	<0.06	<0.06	<0.06	<0.06	0.06	<0.06	<0.06	≥0.25 <sup>4</sup>			
4. cefotaxime	0.06	0.06	<0.06	<0.06	<0.06	<0.06	<0.06	<0.06	≥0.125 <sup>4</sup>			
5. imipenem	0.25	0.125	0.5	0.5	0.25	1	0.125	0.5	≥0.5 <sup>4</sup>	<i>soxS</i> <i>marA</i> <i>tolC</i>	efflux pump	
6. gentamicin	32	32	>32	16	16	32	>32	32	≥2 <sup>4</sup>	<i>acrD</i> <sup>2</sup> <i>kdpE</i> <sup>3</sup>	efflux pump	
7. oxytetracycline	>32	1	0.5	0.5	1	2	1	>32	≥8 <sup>4</sup>	<i>tetB</i> <i>tetR</i> <i>mdfA</i> <sup>2</sup>	efflux pump	
8. doxycycline	32	2	1	1	1	2	2	32	≥4 <sup>4</sup>			
9. sulfamethoxazole	>128	>128	>128	128	>128	>128	>128	>128	>64 <sup>4</sup>	<i>sul2</i> <sup>1,3</sup>	target replacement	
10. trimetoprim	0.5	0.5	<0.25	<0.25	<0.25	<0.25	<0.25	<0.25	≥2 <sup>4</sup>			
11. potent sulphonamide*	16	2	4	2	2	8	4	1	≥0.5 <sup>4</sup>	<i>sul2</i> <sup>1,3</sup>	target replacement	
12. enrofloxacin	<0.06	<0.06	<0.06	0.25	0.25	<0.06	1	4	≥2 <sup>5</sup>	<i>acrA</i> <i>acrB</i> <i>tolC</i>	efflux pump	
										<i>gyrA</i> <i>qnrS1</i> <sup>1,3</sup>	target alteration	
13. colistin	0.25	0.25	0.125	0.25	0.25	0.125	0.25	0.25	≥2 <sup>4</sup>	<i>ugd</i> <sup>3</sup>	envelope overexpression	

\* sulfamethoxazole and trimetoprim, <sup>1</sup>plasmid, <sup>2</sup>phage, <sup>3</sup>MGE (mobile genetic elements), <sup>4</sup>EUCAST, <sup>5</sup>CLSI

which *ampH* is on a plasmid, *ampC* is an MGE and the *bla*<sub>TEM-1</sub> gene is on a plasmid and is also an MGE. The former two are classified by Ambler as Class-C β-lactamase, the *bla*<sub>TEM-1</sub> gene is a broad-spectrum Class-A β-lactamase and able to hydrolyse the first generation cephalosporins (Mittal et al., 2007; Lister et al., 2009). Resistance to cephalosporins is not phenotypically expressed, despite the fact that the *Escherichia coli* bacterial species carry a number of these genes. In the case of imipenem, the *soxS*, *marA* and *tolC* genes may be responsible for the emergence of resistance, of which the *soxS* (Aly et al., 2015) and *marA* (Cohen et al., 1988) genes are regulator genes responsible for the upregulation of the *acrAB* efflux pump system, complemented by the subprotein encoded by the *tolC* gene, thus forming a multidrug efflux pump (Tikhonova et al., 2011). The *acrD* gene expresses a phage-encoded aminoglycoside efflux pump (Rosenberg et al., 2000) and *kdpE* is also an aminoglycoside efflux pump encoding gene (Freeman et al., 2013). The emergence of resistance to tetracyclines is due to *tetB* and *tetR* as MFS-type efflux pump encoding genes and the *mdfA* gene is an efflux pump on a phage (Roberts, 2005). The *sul2* gene is on the plasmid is also an MGE, encoding sulphonamide resistance (Sköld, 2001). In the case of

fluoroquinolones, the emerging resistance is attributed to the multidrug efflux pumps *acrA*, *acrB* and *tolC* and in addition, point mutations in the enzyme encoded by the *gyrA* gene prevent binding of fluoroquinolones to the DNA gyrase alpha subunit (Webber et al., 2017). The *qnrS1* gene is a plasmid-mediated, mobile gene that prevents drug binding (Hata et al., 2005). No phenotypic resistance was observed with colistin, but it should be noted that the *ugd* gene encoding increased arabinose synthesis in the lipid layer was found as an MGE (Gunn et al., 1998).

The study of ARGs entering the human body by any means is a critical One Health concept. In the case of *E. coli* in particular, the diversity of ARGs is well observed. Strains harbouring ARGs are given the opportunity to interact with other non-pathogenic bacteria and horizontal gene transfer occurs. This is particularly likely if the ARG is on a mobile DNA gene sequence (*ampC*, *uhpT*, *mdtG*, *msbA*, *qnrS1*, *sul2*, *bla*<sub>TEM-1</sub>, *tolC*, *ugd*). This is of relevance from a human health perspective, for genes responsible for broad-spectrum β-lactamase production (*bla*<sub>TEM-1</sub>) and resistance to AMEG B class antibiotics such as colistin (*ugd*), fluoroquinolones (*qnrS1*) and generation 3–4 cephalosporins (*tolC*). Quinolone resistance has been reported from Hungary several



times, both from human and animal origin, which is an emerging concern in public health (Szabó et al., 2008; Szmolka et al., 2011).

No *mcr1* gene was found, which is important for resistance to colistin. In another study, where the the resistance gene pool of *E. coli* in broiler chickens from Hungary was investigated, this *mcr1* gene was also absent, probably due to strict regulations (Adorján et al., 2020). However, the emergence of *mcr-1* in *E. coli* has recently been reported in Hungary (Szmolka et al., 2023). This gene has also been recently identified in different *E. coli* strains from South Africa (Ramatla et al., 2023). The *pmrE* gene was exclusively chromosomal, although the *pmrE* (*ugd*) gene may be a problem due to its mobility, but these were not expressed. The *marA* gene should be highlighted, as an important regulator gene in the function of the MDR-type *acrAB* efflux pump system and is also responsible for the down-regulation of porin channels through the regulation of the *ompF* gene. Genes encoding macrolide resistance would only be significant if they were mobile, the same being the case for fosfomycin. The presence of the *gyrA* gene mutation is not advantageous, even though it is not mobile. Due its coding and mobility, the *qnrS1* gene on plasmids and the mobility of the *sul2* gene, as well as the presence of the *ampC* gene may also be the matter of One Health concern.

## CONCLUSIONS

Our results suggest that the use of genetic analysis to map bacterial resistome does not necessarily indicate phenotypic expression, despite the identification of individual genes. The results of MIC studies reflect the correlation between the emergence of resistance to certain active substances and the presence of respective ARGs.

The frequency of mobile genetic elements generally increases the likelihood of gene spread. The spread of AMR to livestock and to the different products of livestock, as well as to humans coming into contact with animals, is now proven to determine the structure of similar resistances. The most relevant indicator in this respect is *E. coli* (Luiken et al., 2019; Van Gompel et al., 2020; Tóth et al., 2021). This is exemplified in our study, where we identified the gene *TEM-1*, which is one of the important broad-spectrum  $\beta$ -lactamases in veterinary and public clinical use. The widespread distribution of several of these AMRGs is due to the fact that their gene is often carried on self-transmissible or mobilizable plasmids, making it capable of rapid horizontal spread, also among different enterobacterial species (Szabó et al., 2008; Szmolka et al., 2011; Perilli et al., 2002) and they are detected all around the world (Chotinantakul et al., 2022; Ghenea et al., 2022; Zhang et al., 2022).

For the precise elucidation of the underlying genes responsible for driving each phenotypically manifested resistance, we recommend conducting further transcriptomic studies. It is also necessary to carry out extensive surveys and to identify and minimise potential sources of risks for the spread of AMR.

**Data availability:** Sequences generated in this study are available under [1028257 BioProject ID](https://www.ncbi.nlm.nih.gov/bioproject/1028257).

## ACKNOWLEDGEMENTS

Prepared with the professional support of the Doctoral Student Scholarship Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology Financed from the National Research, Development and Innovation Fund (KDP-1-4/PALY-2021). Supported by Normative Research Funding Committee (NRC), University of Veterinary Medicine Budapest. Project no. RRF-2.3.1-21-2022-00001 has been implemented with the support provided by the Recovery and Resilience Facility (RRF), financed under the National Recovery Fund budget estimate, RRF-2.3.1-21 funding scheme.

## REFERENCES

- Adorján, A., Makrai, L., Mag, T., Jánosi, S., Könyves, L. and Tóth, I. (2020): High frequency of multidrug-resistant (MDR) atypical Enteropathogenic Escherichia coli (aEPEC) in broilers in Hungary. *Front Vet. Sci* 7, 511.
- Alcock, B. P., Huynh, W., Chalil, R., Smith, K. W., Raphenya, A. R., Wlodarski, M. A., Edalatmand, A., Petkau, A., Syed, S. A., Tsang, K. K., Baker, S. J. C., Dave, M., McCarthy, M. C., Mukiri, K. M., Nasir, J. A., Golbon, B., Imtiaz, H., Jiang, X., Kaur, K., Kwong, M., Liang, Z. C., Niu, K. C., Shan, P., Yang, J. Y. J., Gray, K. L., Hoad, G. R., Jia, B., Bhandu, T., Carfrae, L. A., Farha, M. A., French, S., Gordzevich, R., Rachwalski, K., Tu, M. M., Bordeleau, E., Dooley, D., Griffiths, E., Zubyk, H. L., Brown, E. D., Maguire, F., Beiko, R. G., Hsiao, W. W. L., Brinkman, F. S. L., Van Domselaar, G. and McArthur, A. G. (2023): CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res.* 51, D690–D699.
- Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., Min, S. Y., Miroshnichenko, A., Tran, H.-K., Werfalli, R. E., Nasir, J. A., Oloni, M., Speicher, D. J., Florescu, A., Singh, B., Faltyn, M., Hernandez-Koutoucheva, A., Sharma, A. N., Bordeleau, E., Pawlowski, A. C., Zubyk, H. L., Dooley, D., Griffiths, E., Maguire, F., Winsor, G. L., Beiko, R. G., Brinkman, F. S. L., Hsiao, W. W. L., Domselaar, G. V. and McArthur, A. G. (2020): CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res.* 48, D517–D525.
- Alvarez Narvaez, S., Shen, Z., Yan, L., Stenger, B. L. S., Goodman, L. B., Lim, A., Nissly, R. H., Nair, M. S., Zhang, S. and Sanchez, S. (2022): Optimized conditions for *Listeria*, *Salmonella* and *Escherichia* whole genome sequencing using the Illumina iSeq100 platform with point-and-click bioinformatic analysis. *PLoS One* 17: e0277659.



- Aly, S. A., Boothe, D. M. and Suh, S.-J. (2015): A novel alanine to serine substitution mutation in SoxS induces overexpression of efflux pumps and contributes to multidrug resistance in clinical *Escherichia coli* isolates. *J. Antimicrob. Chemother.* **70**, 2228–2233.
- Andrews, S. (2012): FastQC A Quality Control Tool for High Throughput Sequence Data.
- Bidmos, F. A., Siris, S., Gladstone, C. A. and Langford, P. R. (2018): Bacterial vaccine antigen discovery in the reverse vaccinology 2.0 era: progress and challenges. *Front. Immunol.* **9**.
- Boerlin, P., Travis, R., Gyles, C. L., Reid-Smith, R., Janecko, N., Lim, H., Nicholson, V., McEwen, S. A., Friendship, R. and Archambault, M. (2005): Antimicrobial resistance and virulence genes of *Escherichia coli* isolates from swine in Ontario. *Appl. Environ. Microbiol.* **71**, 6753–6761.
- Chan, E. Y. (2009): Next-generation sequencing methods: impact of sequencing accuracy on SNP discovery. *Methods Mol. Biol.* **578**, 95–111.
- Chotinantakul, K., Chusri, P. and Okada, S. (2022): Detection and characterization of ESBL-producing *Escherichia coli* and additional co-existence with *mcr* genes from river water in northern Thailand. *PeerJ* **10**, e14408.
- Clinical and Laboratory Standards Institute (2018): CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Wayne, PA, Clinical and Laboratory Standards Institute.
- Cohen, S. P., McMurry, L. M. and Levy, S. B. (1988): *marA* locus causes decreased expression of *OmpF* porin in multiple-antibiotic-resistant (Mar) mutants of *Escherichia coli*. *J. Bacteriol.* **170**, 5416–5422.
- El-Attar, L. M. R., Scott, S., Goh, S. and Good, L. (2012): A pestivirus DNA vaccine based on a non-antibiotic resistance *Escherichia coli* essential gene marker. *Vaccine* **30**, 1702–1709.
- EUCAST, T. (2015): European Committee on Antimicrobial Susceptibility Testing, Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 5.0, 2015.
- Freeman, Z. N., Dorus, S. and Waterfield, N. R. (2013): The KdpD/KdpE two-component system: integrating K<sup>+</sup> homeostasis and virulence. *PLoS Pathog.* **9**, e1003201.
- Ghenea, A. E., Zlatian, O. M., Cristea, O. M., Ungureanu, A., Mititelu, R. R., Balasoiu, A. T., Vasile, C. M., Salan, A.-I., Iliuta, D., Popescu, M., Udriștoiu, A.-L. and Balasoiu, M. (2022): TEM, CTX-M, SHV genes in ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from clinical samples in a county clinical emergency hospital Romania-prevalence of CTX-M-15. *Antibiotics (Basel)* **11**, 503.
- Gunn, J. S., Lim, K. B., Krueger, J., Kim, K., Guo, L., Hackett, M. and Miller, S. I. (1998): *PmrA*-*PmrB*-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. *Mol. Microbiol.* **27**, 1171–1182.
- Gurevich, A., Saveliev, V., Vyahhi, N. and Tesler, G. (2013): QUAST: quality assessment tool for genome assemblies. *Bioinformatics* **29**, 1072–1075.
- Hata, M., Suzuki, M., Matsumoto, M., Takahashi, M., Sato, K., Ibe, S. and Sakae, K. (2005): Cloning of a novel gene for quinolone resistance from a transferable plasmid in *Shigella flexneri* 2b. *Antimicrob. Agents Chemother.* **49**, 801–803.
- Hernández-Fillor, R. E., Brilhante, M., Marrero-Moreno, C. M., Baez, M., Espinosa, I. and Perreten, V. (2021): Characterization of third-generation cephalosporin-resistant *Escherichia coli* isolated from pigs in Cuba using next-generation sequencing. *Microb. Drug Resist.* **27**, 1003–1010.
- Hyatt, D., Chen, G.-L., Locascio, P. F., Land, M. L., Larimer, F. W. and Hauser, L. J. (2010): Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* **11**, 119.
- Johansson, M. H. K., Bortolaia, V., Tansirichaiya, S., Aarestrup, F. M., Roberts, A. P. and Petersen, T. N. (2021): Detection of mobile genetic elements associated with antibiotic resistance in *Salmonella enterica* using a newly developed web tool: MobileElementFinder. *J. Antimicrob. Chemother.* **76**, 101–109.
- Krawczyk, P. S., Lipinski, L. and Dziembowski, A. (2018): PlasFlow: predicting plasmid sequences in metagenomic data using genome signatures. *Nucleic Acids Res.* **46**, e35.
- Krueger, F., James, F., Ewels, P., Afyounian, E. and Schuster-Boeckler, B. (2021): FelixKrueger/TrimGalore: v0.6.7 - DOI via Zenodo. Zenodo.
- Li, D., Liu, C.-M., Luo, R., Sadakane, K. and Lam, T.-W. (2015): MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. *Bioinformatics* **31**, 1674–1676.
- Lister, P. D., Wolter, D. J. and Hanson, N. D. (2009): Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin. Microbiol. Rev.* **22**, 582–610.
- Luiken, R. E. C., Van Gompel, L., Munk, P., Sarrazin, S., Joosten, P., Dorado-García, A., Borup Hansen, R., Knudsen, B. E., Bossers, A., Wagenaar, J. A., Aarestrup, F. M., Dewulf, J., Mevius, D. J., Heederik, D. J. J., Smit, L. A. M., Schmitt, H. and EFFORT consortium (2019): Associations between antimicrobial use and the faecal resistome on broiler farms from nine European countries. *J. Antimicrob. Chemother.* **74**, 2596–2604.
- Marguerat, S., Wilhelm, B. T. and Bähler, J. (2008): Next-generation sequencing: applications beyond genomes. *Biochem. Soc. Trans.* **36**, 1091–1096.
- Micoli, F., Bagnoli, F., Rappuoli, R. and Serruto, D. (2021): The role of vaccines in combatting antimicrobial resistance. *Nat. Rev. Microbiol.* **19**, 287–302.
- Mittal, S., Mallik, S., Sharma, S. and Viridi, J. S. (2007): Characteristics of beta-lactamases and their genes (*blaA* and *blaB*) in *Yersinia intermedia* and *Y. frederiksenii*. *BMC Microbiol.* **7**, 25.
- Nagy, B., Szmolka, A., Smole Možina, S., Kovač, J., Strauss, A., Schlager, S., Beutlich, J., Appel, B., Lušický, M., Aprikian, P., Pászti, J., Tóth, I., Kugler, R. and Wagner, M. (2015): Virulence and antimicrobial resistance determinants of verotoxigenic *Escherichia coli* (VTEC) and of multidrug-resistant *E. coli* from foods of animal origin illegally imported to the EU by flight passengers. *Int. J. Food Microbiol.* **209**, 52–59.
- O'Neill, J. (2014): Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. London.
- Perilli, M., Dell'Amico, E., Segatore, B., Massis, M. R. de, Bianchi, C., Luzzaro, F., Rossolini, G. M., Toniolo, A., Nicoletti, G. and Amicosante, G. (2002): Molecular characterization of extended-spectrum  $\beta$ -lactamases produced by



- nosocomial isolates of enterobacteriaceae from an Italian nationwide survey. *J. Clin. Microbiol.* **40**, 611–614.
- Prachi, P., Donati, C., Masciopinto, F., Rappuoli, R. and Bagnoli, F. (2013): Deep sequencing in pre- and clinical vaccine research. *PHG* **16**, 62–68.
- Ramatla, T., Tawana, M., Lekota, K. E. and Thekiso, O. (2023): Antimicrobial resistance genes of *Escherichia coli*, a bacterium of “One Health” importance in South Africa: systematic review and meta-analysis. *AIMS Microbiol.* **9**, 75–89.
- Rappuoli, R., Bloom, D. E. and Black, S. (2017): Deploy vaccines to fight superbugs. *Nature* **552**, 165–167.
- Roberts, M. C. (2005): Update on acquired tetracycline resistance genes. *FEMS Microbiol. Lett.* **245**, 195–203.
- Rosenberg, E. Y., Ma, D. and Nikaido, H. (2000): AcrD of *Escherichia coli* is an aminoglycoside efflux pump. *J. Bacteriol.* **182**, 1754–1756.
- Roux, S., Enault, F., Hurwitz, B. L. and Sullivan, M. B. (2015): VirSorter: mining viral signal from microbial genomic data. *PeerJ* **3**, e985.
- Sahin-Tóth, J., Kovács, E., Tóthpál, A., Juhász, J., Forró, B., Bányai, K., Havril, K., Horváth, A., Ghidán, Á. and Dobay, O. (2021): Whole genome sequencing of coagulase positive staphylococci from a dog-and-owner screening survey. *PLoS One* **16**, e0245351.
- Sköld, O. (2001): Resistance to trimethoprim and sulfonamides. *Vet Res.* **32**, 261–273.
- Szabó, D., Kocsis, B., Rókusz, L., Szentandrassy, J., Katona, K., Kristóf, K. and Nagy, K. (2008): First detection of plasmid-mediated, quinolone resistance determinants qnrA, qnrB, qnrS and aac(6′)-Ib-cr in extended-spectrum  $\beta$ -lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary. *J. Antimicrob. Chemother.* **62**, 630–632.
- Szmolka, A., Fortini, D., Villa, L., Carattoli, A., Anjum, M. F. and Nagy, B. (2011): First report on IncN plasmid-mediated quinolone resistance gene qnrS1 in porcine *Escherichia coli* in Europe. *Microb. Drug Resist.* **17**, 567–573.
- Szmolka, A., Gellért, Á., Szemerits, D., Rapcsák, F., Spisák, S. and Adorján, A. (2023): Emergence and genomic features of a mcr-1 *Escherichia coli* from Duck in Hungary. *Antibiotics (Basel)* **12**, 1519.
- Tikhonova, E. B., Yamada, Y. and Zgurskaya, H. I. (2011): Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC. *Chem Biol.* **18**, 454–463.
- Tóth, A. G., Papp, M., Jerzsele, Á., Borbély, F., Reibling, T., Makrai, L. and Solymosi, N. (2021): Szoptató kocák bélsárrezisztómja egy hazai nagy létszámú sertésállományban. *MÁL* **143**, 203–214.
- Van Gompel, L., Luiken, R. E. C., Hansen, R. B., Munk, P., Bouwknegt, M., Heres, L., Greve, G. D., Scherpenisse, P., Jongerius-Gortemaker, B. G. M., Tersteeg-Zijderveld, M. H. G., García-Cobos, S., Dohmen, W., Dorado-García, A., Wagenaar, J. A., Urlings, B. A. P., Aarestrup, F. M., Mevius, D. J., Heederik, D. J. J., Schmitt, H., Bossers, A. and Smit, L. A. M. (2020): Description and determinants of the faecal resistome and microbiome of farmers and slaughterhouse workers: a metagenome-wide cross-sectional study. *Environ. Int.* **143**, 105939.
- Veenemans, J., Overdeest, I. T., Snelders, E., Willemsen, I., Hendriks, Y., Adesokan, A., Doran, G., Brusio, S., Rolfe, A., Pettersson, A. and Kluytmans, J. a. J. W. (2014): Next-generation sequencing for typing and detection of resistance genes: performance of a new commercial method during an outbreak of extended-spectrum-beta-lactamase-producing *Escherichia coli*. *J. Clin. Microbiol.* **52**, 2454–2460.
- Webber, M. A., Buckner, M. M. C., Redgrave, L. S., Ifill, G., Mitchenall, L. A., Webb, C., Iddles, R., Maxwell, A. and Piddock, L. J. V. (2017): Quinolone-resistant gyrase mutants demonstrate decreased susceptibility to triclosan. *J. Antimicrob. Chemother.* **72**, 2755–2763.
- Wintersdorff, C. J. H. von, Penders, J., Niekerk, J. M. van, Mills, N. D., Majumder, S., Alphen, L. B. van, Savelkoul, P. H. M. and Wolffs, P. F. G. (2016): Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol.* **7**, 173.
- Zhang, X., Fang, C., Zhang, J., Hua, W., He, R. and Zhou, M. (2022): Carbapenemase- and colistin resistant *Escherichia coli* strains from children in China: high genetic diversity and first report of bla<sub>NDM-5</sub>, bla<sub>CTX-M-65</sub>, bla<sub>OXA-10</sub>, bla<sub>TEM-1</sub>, and mcr-1.1 genes Co-occurrence in *E. coli* ST156. *Infect Drug Resist.* **15**, 5315–5320.
- Zhang, X., Xiao, S., Jiang, X., Li, Y., Fan, Z., Yu, Y., Wang, P., Li, D., Zhao, X. and Liu, C. (2019): Genomic characterization of *Escherichia coli* LCT-EC001, an extremely multidrug-resistant strain with an amazing number of resistance genes. *Gut Pathog.* **11**, 25.

